Our Medicinal Inorganic Chemistry Research Group works at the interface between inorganic chemistry, organometallic chemistry, medicinal chemistry, chemical biology and biology. Projects undertaken in our laboratory fundamentally aim at answering open scientific questions of current interest in the fields above. We are also interested in developing new imaging techniques and identifying clinically useful compounds which should ultimately be employed to ameliorate different human pathologies. Generally speaking, our scientific pursuit involves the preparation, characterization and application (for biological or medicinal purposes) of metal-based complexes and the surface functionalization of bio-inspired materials.

International Chemistry
Department of Chemistry


PhD Students Seminars
Group Meetings


Rimini, 05-10.07.2020
Reykjavik, 16-20.08.2020


Antiplasmodial Activity and In Vivo Bio-Distribution of Chloroquine Molecules Released with a 4-(4-Ethynylphenyl)-Triazole Moiety from Organometallo-Cobalamins.

Organometallic derivatives of cobalamin act as a scaffold for the delivery of the same antimalarial drug to both erythro- and hepatocytes. Read more about it here.

Three-Dimensional Mid-Infrared Tomographic Imaging of Endogenous and Exogenous Molecules in a Single Intact Cell with Subcellular Resolution.

A method and protocols to obtain tomographic 3D images of the endogenous and exogenous cellular distribution of molecules. The technique is based on tilt-series infrared tomography with a standard benchtop infrared microscope. This approach gives access to the quantitative 3D distribution of molecular components based on the intrinsic contrast provided by the sample. Read more about it here.

Slow-​targeted release of a ruthenium anticancer agent from vitamin B12 functionalized marine diatom microalgae.

Our group prepared a new bio-inspired material designed for targeted delivery of poorly water-soluble inorganic anticancer drugs, with a focus on colorectal cancer. Read more about it here. See video.

Heme Oxygenase-1/Carbon Monoxide System
and Embryonic Stem Cell Differentiation
and Maturation into Cardiomyocytes.

Dr. Hagir Suliman and Dr. Claude Piantadosi (Duke University Medical Center, USA) provide evidence that our B12-ReCORM-2 molecule has the capacity to augment cardiomyogenesis via a defined mitochondrial pathway and that the same has unique therapeutic potential for targeting embryonic stem cell maturation in cardiac disease. The differentiation of embryonic stem cells into energetically efficient cardiomyocytes contributes to functional cardiac repair and is envisioned to ameliorate progressive degenerative cardiac diseases. Read more about it here.

This site was designed with the
website builder. Create your website today.
Start Now